While many say the pharmaceutical industry is likely legal marijuana’s biggest enemy, it looks like one pharmaceutical company may be making serious strides to prove once and for all marijuana’s medical benefits.
GW Pharmaceuticals, a British drug company, has announced that they had been testing a cannabis-based mediation over the past few years which is showing serious potential in treating brain cancer.
Specifically, the type of brain cancer that their product has been focusing on is glioblastoma multiforme, which typically causes death within about two years. GW Pharma says their new cannabis-based product is
“We believe that the signals of efficacy demonstrated in this study further reinforce the potential role of cannabinoids in the field of oncology and provide GW with the prospect of a new and distinct cannabinoid product candidate in the treatment of glioma.”
Unfortunately, the study did not distinguish between the effects of THC and CBD. Patients were given a mix of the two substances, along with a chemotherapy drug called Temozolomide. The study, however, was promising, as patients who received the cocktail shows an 83% survival rate as opposed to 53% in those who were given the placebo treatment.
Along with this effort, GW is also working on releasing a cannabis spray called Epidiolex for people who suffer from epilepsy. All of GW’s efforts point to a new possibility for medical marijuana patients to begin relying on their traditional drug providers for medication rather than their state’s medical marijuana program.
Many medical marijuana users would say they would prefer to stick with the flower rather than these new prescription marijuana drugs. However, it is still a positive sign for the industry that traditional pharmaceutical companies are moving in the direction of accepting and marketing marijuana-based products.